Contradictory findings exist about association of angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) with lung cancer development. This was a retrospective observational cohort study that used data from 7 hospitals in Korea, converted to the Observational Medical Outcomes Partnership Common Data Model. The primary outcome was occurrence of lung cancer. A total of 207,794 patients across the 7 databases was included in the final analysis; 33,230 (16%) were prescribed ACEi and 174,564 (84%) were prescribed ARB. Crude analysis adjusted for sex and age showed higher incidence of lung cancer in the ACEi group compared to the ARB group (hazard ratio [HR], 1.46; 95% confidence rate [CI], 1.08–1.97). After propensity-score matching, 30,445 pairs were generated, and there was no difference in incidence of lung cancer between the two groups (HR, 0.93; 95% CI, 0.64–1.35). Patients prescribed ACEi showed no difference in incidence of lung cancer development compared to those using ARB. This finding provides evidence on the association between ACEi and occurrence of lung cancer.

关于血管紧张素转换酶抑制剂 (ACEi) 和血管紧张素受体阻滞剂 (ARB) 与肺癌发展的关联存在矛盾的发现。这是一项回顾性观察队列研究，使用来自韩国 7 家医院的数据，转换为观察性医疗结果伙伴关系通用数据模型。主要结果是肺癌的发生。7 个数据库中的 207,794 名患者被纳入最终分析；33,230 (16%) 名患者接受了 ACEI，174,564 (84%) 名患者接受了 ARB。调整性别和年龄的粗略分析显示，与 ARB 组相比，ACEi 组的肺癌发病率更高（风险比 [HR]，1.46；95% 置信率 [CI]，1.08-1.97）。倾向得分匹配后，生成了 30,445 对，并且两组之间的肺癌发病率没有差异（HR，0.93；95% CI，0.64-1.35）。与使用 ARB 的患者相比，使用 ACEI 的患者在肺癌发生率方面没有差异。这一发现为ACEi与肺癌发生之间的关联提供了证据。